A carregar...

Serotonin augmentation therapy by escitalopram has minimal effects on amyloid-β levels in early-stage Alzheimer’s-like disease in mice

BACKGROUND: Dysfunction of the serotonergic (5-HTergic) system has been implicated in the cognitive and behavioural symptoms of Alzheimer’s disease (AD). Accumulation of toxic amyloid-β (Aβ) species is a hallmark of AD and an instigator of pathology. Serotonin (5-HT) augmentation therapy by treatmen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Alzheimers Res Ther
Main Authors: von Linstow, Christian Ulrich, Waider, Jonas, Grebing, Manuela, Metaxas, Athanasios, Lesch, Klaus Peter, Finsen, Bente
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5596844/
https://ncbi.nlm.nih.gov/pubmed/28899417
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-017-0298-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!